StockUS listing USDMRANASDAQHealthcareCapital Destroyer

Damora Therapeutics, Inc.(DMRA) Stock Analysis | Healthcare

USD --+0.00%
Reward36Moderate
Risk56Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.44Bn
Reward Ratingⓘ36 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ56 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DMRA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Damora Therapeutics, Inc.?

, a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.

AI Brief Pro

The brief on Damora Therapeutics, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Damora Therapeutics, Inc.?

, a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.44B, and a P/E ratio of 13.6x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (36)
Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio13.5789
Beta1.507
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
0
112,500 shares
$253k
3-6months
1245 shares
$7k
0
6-9months
0
0
9-12months
31,090 shares
$23k
0